Behavioral evidence for μ-opioid and 5-HT2A receptor interactions

被引:25
作者
Marek, GJ
机构
[1] Pfizer Inc, Groton Labs, Groton, CT 06340 USA
[2] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA
关键词
phenethylamine; hallucinogen; 5-HT; (5-hydroxytryptamine; serotonin); mu-opioid receptor; head shake; DOI; 5-HT2A receptor; buprenorphine; fentanyl;
D O I
10.1016/S0014-2999(03)01971-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Electrophysiological studies have demonstrated a physiological interaction between 5-HT2A and mu-opioid receptors in the medial prefrontal cortex. Furthermore, behavioral studies have found that phenethylamine hallucinogens induce head shakes when directly administered into the medial prefrontal cortex. The receptor(s) by which morphine suppresses head shakes induced by serotonin agonists have not been characterized. We administered g-opioid receptor agonists and antagonists to adult male Sprague-Dawley rats prior to treatment with the phenethylamine hallucinogen 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), which is known to induce head shakes via 5-HT2A receptors. The suppressant action of the moderately selective mu-opioid receptor agonist, buprenorphine (ID50 similar to 0.005 mg/ kg, i.p.; a mu-opioid receptor partial agonist and kappa-opioid receptor antagonist) was blocked by naloxone and pretreatment with the irreversible mu-opioid receptor antagonist clocinnamox. Another mu-opioid receptor agonist fentanyl also suppressed DOI-induced head shakes. In contrast, a delta-opioid receptor agonist was without effect on DOI-induced head shakes. Thus, activation of mu-opioid receptors can suppress head shakes induced by hallucinogenic drugs. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:77 / 83
页数:7
相关论文
共 44 条
[1]  
Alvaro J. D., 1998, Society for Neuroscience Abstracts, V24, P1369
[2]   WET-DOG SHAKE BEHAVIOR IN RAT - POSSIBLE QUANTITATIVE MODEL OF CENTRAL 5-HYDROXYTRYPTAMINE ACTIVITY [J].
BEDARD, P ;
PYCOCK, CJ .
NEUROPHARMACOLOGY, 1977, 16 (10) :663-670
[3]   CORRESPONDENCE BETWEEN 5-HT2 RECEPTORS AND SEROTONERGIC AXONS IN RAT NEOCORTEX [J].
BLUE, ME ;
YAGALOFF, KA ;
MAMOUNAS, LA ;
HARTIG, PR ;
MOLLIVER, ME .
BRAIN RESEARCH, 1988, 453 (1-2) :315-328
[4]   BUPRENORPHINE TREATMENT OF REFRACTORY DEPRESSION [J].
BODKIN, JA ;
ZORNBERG, GL ;
LUKAS, SE ;
COLE, JO .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1995, 15 (01) :49-57
[5]   A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine [J].
Carpenter, LL ;
Yasmin, S ;
Price, LH .
BIOLOGICAL PSYCHIATRY, 2002, 51 (02) :183-188
[6]  
COHEN MR, 1984, BIOL PSYCHIAT, V19, P825
[7]   A METHOD FOR ASSESSING EFFECTS OF DRUGS ON CENTRAL ACTIONS OF 5-HYDROXYTRYPTAMINE [J].
CORNE, SJ ;
WARNER, BT ;
PICKERING, RW .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1963, 20 (01) :106-&
[8]   AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT [J].
COWAN, A ;
LEWIS, JW ;
MACFARLANE, IR .
BRITISH JOURNAL OF PHARMACOLOGY, 1977, 60 (04) :537-545
[9]   POSSIBLE ANTIDEPRESSIVE EFFECTS OF OPIOIDS - ACTION OF BUPRENORPHINE [J].
EMRICH, HM ;
VOGT, P ;
HERZ, A .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1982, 398 (DEC) :108-112
[10]   Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone [J].
Ferreri, M ;
Lavergne, F ;
Berlin, I ;
Payan, C ;
Puech, AJ .
ACTA PSYCHIATRICA SCANDINAVICA, 2001, 103 (01) :66-72